Welcome to the Bladder Cancer website! Please take a look around at the content of the journal and other features of this community portal, including joining the discussion thread about the latest challenging cases, or taking a look at the Clinical Trials Corner.

Bladder Cancer is classified as the official journal of the Bladder Cancer Advocacy Network (BCAN). Read more about this new partnership to support a readily accessible information platform to serve the bladder cancer research and clinical practice communities via: tiny.cc/BLC-BCAN_PR

Cedars-Sinai Cancer investigators were part of a team that identified a specific type of bladder cancer most likely to resist first-line treatment. Their study could guide clinicians toward more aggressive treatment or more targeted therapies for some patients with specific subtypes of the disease, ultimately saving lives.